NGM Biopharmaceuticals Updates IPO Filing – Will Raise Over $122 Million

March 26, 2019

NGM Updated its IPO filing to include an estimated price range of  $14 to $16 per share. If all available shares are purchased, the IPO will raise more than $122 Million. The company intends to trade under the symbol, “NGM.”

Merck is a current shareholder and strategic collaborator with NGM. Merck will purchase a number of shares at the public offering price that will result in Merck owning 19.9% of outstanding shares once the offering is complete.

NGM is a clinical-stage bio pharma that has seven candidates in development. Its most advanced candidate in terms of development stage is NGM 282 for non-alcoholic  steatohepatitis (NASH). The drug will enter Ph Iib in mid 2019.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.